Skip to main content
HighlightsHighlights Archive

Media Monitoring: 10th-16th September

By September 16, 2022No Comments

COVID infections in UK fall to lowest level since October 2021

  • The ONS stated that fewer than a million people had the virus in the last week of August, approximately one in 70
  • The represents a massive fall from mid-July, when one in 15 people had COVID
  • This comes at a time when the booster jab rollout has begun – with care home residents the first to be protected


Results from Galleri blood test for cancer hugely promising

  • The much-vaunted Galleri blood test has yielded excellent results following a Pathfinder study which tested 6,600 adults aged 50 or over.
  • 92 new cases, many at an early and treatable stage, were picked up and three-quarters were not routinely screened for
  • NHS England are currently trialing the test with 165,000 participants, with results expected next year


(Paywall) Hunt begins for genes to unlock mystery of ME

  • A Times piece that examines the search for a genetic link to ME


Breath sampling device proven to be 100% effective

  • The PBM-HALE device can study deep lung infections by collecting aerosol from patients’ breath, preventing the need for invasive diagnostic interventions
  • Results show that it had 100% accuracy when testing for COVID-19


Empowering people across integrated care systems through digital technology

  • A fantastic article which examines the immense benefit that digital technology can have for patients


NIHR revamp to go ahead in 2024

  • The NIHR’s Clinical Research Networks are set to be renamed NIHR Research Delivery Networks (RDN) to better reflect the scope of their work
  • The networks will seek to support critical clinical trials and patient studies
  • England will be supported via 12 delivery networks, working with the national Coordinating Centre to establish a collaborative RDN leadership function so the regional networks can work together to impart their vision across the nation


Study finds new biomarker for heart failure

  • Levels of endotrophin, a protein fragment, in the blood can be used as a reliable biomarker for common heart failure, a study has shown
  • Researchers at the Perelman School of Medicine at the University of Pennsylvania have stated that testing for endotrophin levels could be a standard part of a cardiologist’s armoury in future, particularly for heart failure with preserved ejection fraction (HFpEF)
  • Companies are now working to develop an endotrophin blood test for possible future use in assessing HFpEF patients

Natalie Creaney